Contact
searchSearch
HMP Global
Login

Prostate Cancer

Prostate Cancer
Specialty Channel
FDA Approval
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI for PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer
08/03/2026
Emily Estrada
The FDA has approved lutetium Lu 177 vipivotide tetraxetan in combination with androgen receptor pathway inhibitor therapy for patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The approval was based on results from...
The FDA has approved lutetium Lu 177 vipivotide tetraxetan in combination with androgen receptor pathway inhibitor therapy for patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The approval was based on results from...
The FDA has approved lutetium Lu...
08/03/2026
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
News
Aglatimagene Plus Radiotherapy Improves Disease-Free Survival in Localized Prostate Cancer
07/09/2026
Emily Estrada
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03...
07/09/2026
Oncology
Kim Chi, MD
Videos
PR21 PLUTO Supports Flexible Sequencing of Docetaxel and Lutetium-177 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
Kim Chi, MD
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover...
06/19/2026
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
David Cade, MD
Videos
TLX591 Shows Prolonged Tumor Retention With Limited Off-Target Radiation Exposure in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
David Cade, MD
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the...
06/19/2026
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
Neeraj Agarwal, MD
Videos
TALAPRO-3 Establishes Talazoparib Plus Enzalutamide as a New Standard for HRR-Altered Metastatic Hormone-Sensitive Prostate Cancer
06/18/2026
Neeraj Agarwal, MD
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-3 trial showing that talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% and significantly delayed disease progression across BRCA and...
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-3 trial showing that talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% and significantly delayed disease progression across BRCA and...
Neeraj Agarwal, MD, discusses...
06/18/2026
Oncology
Michael Morris, MD
Videos
Convo-1α Produces Durable Responses in Patients Previously Treated With PSMA Radioligand Therapy
06/18/2026
Michael Morris, MD
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses...
06/18/2026
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
Alicia Morgans, MD
Videos
Enzalutamide Associated with Increased Cognitive Decline in in Advanced Prostate Cancer
06/12/2026
Alicia Morgans, MD
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses...
06/12/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
Mark Garzotto, MD
Videos
Intratumoral Adenoviral Therapy Combined With Radiation in Prostate Cancer
05/27/2026
Mark Garzotto, MD
Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.
Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.
Mark Garzotto, MD, discusses a...
05/27/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology

News

News
Aglatimagene Plus Radiotherapy Improves Disease-Free Survival in Localized Prostate Cancer
07/09/2026
Emily Estrada
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03...
07/09/2026
Oncology
FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology
News
Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer
05/20/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial...
05/20/2026
Oncology
FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
News
Early G-CSF Use Supports Maintenance of Docetaxel Dose Intensity in Metastatic Hormone-Sensitive Prostate Cancer
04/29/2026
Emily Estrada
Results from a post hoc analysis of the phase 3 ARASENS trial demonstrated that most patients with metastatic hormone-sensitive prostate cancer maintained effective docetaxel dose intensity through early G-CSF use and appropriate dose...
Results from a post hoc analysis of the phase 3 ARASENS trial demonstrated that most patients with metastatic hormone-sensitive prostate cancer maintained effective docetaxel dose intensity through early G-CSF use and appropriate dose...
Results from a post hoc analysis...
04/29/2026
Oncology
News
131I-LNTH-1095 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
04/10/2026
Stephanie Holland
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW...
04/10/2026
Radiopharmaceutical Education Institute
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
FDA Approval
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute

Interactive Features

FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
Quiz
Improving Detection of Clinically Significant Prostate Cancer
01/15/2024
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the...
01/15/2024
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Quiz
Biweekly vs Triweekly Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial
11/10/2023
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
11/02/2022
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found...
11/02/2022
Oncology
Quiz
Quiz: Enzalutamide Plus Testosterone Suppression for Metastatic Hormone-Sensitive Prostate Cancer
09/02/2022
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating...
09/02/2022
Oncology
Quiz
Quiz: Does the Polaris Test Prognosticate Risk of Metastasis in Prostate Cancer?
07/21/2022
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available...
07/21/2022
Oncology
Test Your Knowledge
Quiz: Can the Prolaris Test Estimate Metastasis in Prostate Cancer?
09/02/2021
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with...
09/02/2021
Oncology
Test Your Knowledge
Quiz: Can Large Antibodies Target PSMA Expression During mCRPC Treatment?
07/29/2021
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small...
07/29/2021
Oncology

Recent News

News
Aglatimagene Plus Radiotherapy Improves Disease-Free Survival in Localized Prostate Cancer
07/09/2026
Emily Estrada
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03...
07/09/2026
Oncology
FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology
News
Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer
05/20/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial...
05/20/2026
Oncology
FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
News
Early G-CSF Use Supports Maintenance of Docetaxel Dose Intensity in Metastatic Hormone-Sensitive Prostate Cancer
04/29/2026
Emily Estrada
Results from a post hoc analysis of the phase 3 ARASENS trial demonstrated that most patients with metastatic hormone-sensitive prostate cancer maintained effective docetaxel dose intensity through early G-CSF use and appropriate dose...
Results from a post hoc analysis of the phase 3 ARASENS trial demonstrated that most patients with metastatic hormone-sensitive prostate cancer maintained effective docetaxel dose intensity through early G-CSF use and appropriate dose...
Results from a post hoc analysis...
04/29/2026
Oncology
News
131I-LNTH-1095 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
04/10/2026
Stephanie Holland
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW...
04/10/2026
Radiopharmaceutical Education Institute
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
FDA Approval
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use